Menu
There is a need to enhance the clinicians’ ability to diagnose Parkinson’s disease and atypical PD, especially in early stages.
This biomarker test can detect α-synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Most physicians are comfortable making the clinical diagnosis of PD; however, there is still a significant amount of patients who are not easily differentiated from other movement disorders.
There is a biomarker test that can help confirm PD or atypical PD. The SAAmplify-ɑSYN Test provides highly sensitive and specific detection of α-synuclein aggregates and has received FDA Breakthrough product designation for use to support the diagnosis of Parkinson’s disease.
“The accuracy of Parkinson’s Disease clinical diagnosis has not significantly improved in the last 25 years. This is particularly noted in the early stages of disease, where response to dopaminergic treatment is less defined and hallmarks of alternative diagnoses such as atypical parkinsonism may not have emerged.” Reference
“Accuracy of clinical diagnosis performed by movement disorders experts is 79.6% of initial assessment to 83.9% of refined diagnosis after follow-up.“ Reference
“The neuropathological hallmark of PD is the abnormal accumulation and aggregation of alpha synuclein protein (α-Syn) in form of Lewy bodies and Lewy neurites.” Reference
Download the SAAmplify-ɑSYN Test Specification Sheet for details.
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
